|
Accession Number
|
PB2013-500001
|
|
Title
|
A5221: Timing of Antiretroiral Theapy for HIV-1 Infection and Tuberculosis.
|
|
Publication Date
|
2012
|
|
Media Count
|
1one CD-ROM
|
|
Personal Author
|
N/A
|
|
Abstract
|
A5221/STRIDE was strategy trial to evaluate the timing of antiretroviral therapy (ART) during tuberculosis therapy. It included both patients with confirmed tuberculosis and those with suspected tuberculosis, since in clinical practice, the decision to start or delay ART must often be made before there is a definitive diagnosis of tuberculosis (a reflection of the current limitations of and access to tuberculosis diagnostics). Patients from a wide geographic spectrum were included to maximize the generalizability of the findings and to inform policy.
|
|
Keywords
|
ACTG(AIDS Clinical Trials Group)
AIDS
Antiretroviral therapy
Clinical groups
Controlled trian
Datafile
HIV(Human immunodeficiency viruses)
Infection
Patients
SAS(Statistical Analysis System)
STRIDE
Treatment
Tuberculosis
|
|
|
Source Agency
|
National Institute of Allergy and Infectious Disease
|
|
NTIS Subject Category
|
57E - Clinical Medicine
57J - Immunology
|
|
Corporate Author
|
Harvard School of Public Health, Boston, MA. Dept. of Biostatistics.
|
|
Document Type
|
Computer data file
|
|
Title Note
|
N/A
|
|
NTIS Issue Number
|
1302
|
|
Contract Number
|
N/A
|
